June 28, 2018 / 8:27 PM / 5 months ago

Biogen raises stake in Samsung Bioepis to 49.9 percent

(Reuters) - Drugmaker Biogen Inc (BIIB.O) said on Thursday it would buy additional shares of Samsung Bioepis Co Ltd worth $700 million to raise its stake in the biosimilar company to 49.9 percent.

Biogen previously owned a 5.4 percent in the company, following a joint venture between the two companies set up in 2012.

Reporting by Nivedita Balu in Bengaluru; Editing by Arun Koyyur

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below